Stifel analyst Justin Keywood Upgrade to Buy @ $6.75“Knight is a specialty pharma company with 90 per cent of sales tied to the LATAM market. We have rated Knight a HOLD, since 2022 with a LATAM discount factored in, impacting investor sentiment and what we expected to be a range-bound stock. However, we see good growth ahead, in Q3 (up 7 per cent) and more materially in Q4 (up 19 per cent), consistent with guidance and setting up for what could be an inflection in 2025 with several new products set to be launched.”